PhaseRx Inc., (PhaseRx) is an RNAi delivery technology company. The company is involved in developing a breakthrough polymer-based system, which enables the systemic delivery of RNAi-based drugs and potentially other macromolecules as therapeutic products. PhaseRx’s intellectual property portfolio includes 15 patent families filed in the world`s major pharmaceutical markets, 4 issued U.S. patents, and over 60 pending applications.